Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • CLL11 study

Combination of chlorambucil and CD20 antibody the new standard as early as 2014?

    • Interviews
    • Oncology
    • RX
  • 3 minute read

In an interview with InFo ONCOLOGY & HEMATOLOGY, Michael Gregor, MD, of Lucerne Cantonal Hospital, talks about the CLL11 trial. It addresses the study population, the most relevant results, and the safety profile of the drugs studied.

Dr. Gregor, how does the CLL11 study differ from other chronic lymphocytic leukemia studies (e.g., in terms of study population)?

Dr. Gregor:
The CLL11 trial is the largest randomized phase III trial to date for CLL patients with comorbidities. The median age of the 780 patients studied was 73 years. The patient population of the CLL11 study is more similar to the typical CLL patient in practice than most previous studies, which predominantly considered younger “fit” patients.

Which results of the CLL11 study do you personally consider to be the most relevant?
The benefit of adding a CD20 antibody to previously used chemotherapy with chlorambucil  was impressive  in terms of response and progression-free survival. The difference between  the two chemoimmunotherapy arms was surprisingly large. Progression-free survival with the combination of chlorambucil and rituximab was 15.2 months, compared with 26.7 months with the combination of chlorambucil and obinutuzumab. A surprising effect was the prolongation of overall survival with the combination of chlorambucil and obinutuzumab compared with the previous standard chemotherapy with chlorambucil in this early analysis after an observation period of almost two years.

What concrete value could the results have for clinical practice in Switzerland in the longer term, or for which patients could obinutuzumab be considered as a supplement to chlorambucil (GClb) in the future in your opinion?
I expect the combination of chlorambucil and a CD20 antibody to become the new standard for CLL patients with more severe comorbidities as early as 2014. To date, only a difference in progression-free survival has been demonstrated between the combination with rituximab and obinutuzumab. If in future analyses the advantage for obinutuzumab continues to increase or if there is even a better overall survival, the combination of chlorambucil and obinutuzumab will very soon become the preferred therapy for most CLL patients with comorbidities.

How do you assess the safety profile of the two compared combinations (obinutuzumab plus chlorambucil/rituximab plus chlorambucil)?
Grade ≥3 adverse events were observed more frequently with the combination of chlorambucil and obinutuzumab than with chlorambucil and rituximab (70% vs. 55%). These were most commonly infusion reactions, which usually occurred only on the first infusion, and neutropenias and thrombocytopenias. In contrast, the infection rate was the same in both study arms with chemoimmunotherapy as with chlorambucil monotherapy. Prophylaxis and therapy of common infusion reactions will be important for use in clinical practice.

What can be said about the dosage, did the GClb dosage chosen in the study prove appropriate, and what contribution did it make to the results?
The infusion regimen and dosing of obinutuzumab were derived from pharmacologic studies. With the regimen used and the significantly higher antibody dose compared with rituximab, the combination of chlorambucil and obinutuzumab was clearly superior to chlorambucil and rituximab. I think, however, that the large difference between the study arms cannot be explained by this alone. Obinutuzumab has significantly increased antigen-mediated cellular toxicity in vitro and greater direct cytotoxicity than rituximab, both of which may lead to the higher efficacy observed in the study.

Interview: Andreas Grossmann

InFo Oncology & Hematology 2014; 2(3): 2-3.

Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • CD20 antibody
  • Chlorambucil
  • CL11
Previous Article
  • Gastric Cancer

Targeted therapies in HER2-positive tumors.

  • Congress Reports
  • Gastroenterology and Hepatology
  • Oncology
  • RX
View Post
Next Article
  • Helicobacter pylori

Eradication for the prevention of gastric cancer?

  • Congress Reports
  • Gastroenterology and Hepatology
  • Oncology
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Latent autoimmune diabetes in adults (LADA)

Looks like type 2, but is type 1

    • Cases
    • Education
    • Endocrinology and Diabetology
    • RX
    • Studies
View Post
  • 6 min
  • Treatment of vitiligo

Focus on patient perspective and disease activity

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Vaccine-preventable respiratory diseases

RSV and pneumococci: recommendations for risk groups

    • Congress Reports
    • General Internal Medicine
    • Infectiology
    • Pediatrics
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 5 min
  • Circadian rhythm in asthma

Chronotherapy can improve control

    • Allergology and clinical immunology
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
View Post
  • 6 min
  • Update on diagnostics, risk stratification and therapy

Acute myeloid leukemia 2025

    • Education
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 4 min
  • New practice guideline for fibromyalgia syndrome

Good times, bad times

    • Congress Reports
    • General Internal Medicine
    • Neurology
    • Pharmacology and toxicology
    • Physical medicine and rehabilitation
    • Rheumatology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 5 min
  • Findings from the TRACK-FA study

Neuroimaging biomarkers in Friedreich’s ataxia

    • Genetics
    • Neurology
    • Pediatrics
    • RX
    • Studies
View Post
  • 12 min
  • Doing sport without fear or risk

Doing sport without fear or risk

    • CME continuing education
    • Endocrinology and Diabetology
    • Pediatrics
    • RX
    • Sports Medicine
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Doing sport without fear or risk
  • 2
    UV protection and skin cancer screening – Update 2025
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Yellow nail and Swyer-James syndrome
  • 5
    Diagnostic indications

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.